Revenue, 2025

USD 4.2 Billion

Forecast, 2035

USD 23.32 Billion

CAGR, 2026-2035

18.7%

Report Coverage

Global

Induced Proximity Molecules Market Trends for 2026

The global induced proximity molecules market size was estimated at USD 4.2 billion in 2025 and is predicted to increase from USD 4.99 billion in 2026 to approximately USD 23.32 billion by 2035, expanding at a CAGR of 18.7% from 2026 to 2035. The induced proximity molecules market is growing because these molecules have the strength to unlock a wide portion of the disease targets that were once thought inaccessible.

Key Takeaways

• Induced proximity molecules sector pushed the market to USD 4.99 billion by 2026.
• Long-term projections show USD 23.32 billion valuation by 2035.
• Growth is expected at a steady CAGR of 18.7% in between 2026 to 2035.
• North America dominated the induced proximity molecules market with a share of 44% in 2025.
• Asia Pacific held 20% share of the market, expected to grow at the fastest CAGR during the forecast period.
• By molecule type, the PROTACs segment held 52% market share in 2025.
• By molecule type, the molecular glues segment held the second-largest market share of 27% in 2025, and is expected to grow at the fastest CAGR during the forecast period.
• By target protein class, the kinases segment held the largest market share of 34% in 2025.
• By target protein class, the transcription factors segment held a significant market share of 22% in 2025, and is expected to grow at the fastest CAGR during the forecast period.
• By therapeutic area, the oncology segment held the largest induced proximity molecules market share of 58% in 2025.
• By therapeutic area, the neurological disorders segment held a notable market share of 14% in 2025, and is expected to grow at the fastest CAGR during the forecast period.
• By end user, the pharmaceutical & biotechnology companies segment held the largest market share of 68% in 2025.
• By end user, the contract research organizations (CROs) segment held a notable market share of 13% in 2025, and is expected to grow at the fastest CAGR during the forecast period.

Market Overview: What are Enteral Feeding Devices?

The induced proximity molecules market is growing, as induced proximity is a significant approach for regulating proteins through loss or gain of function. This innovative mechanism employs proximity-inducing molecules to bring proteins or nucleic acids together to modulate the function of a target and the related cellular processes. Many biotech companies have leveraged the therapeutic potential of the induced proximity approach to develop drugs against a myriad of diseases. The wide range of applicability of this stratergies has expanded to disease areas beyond cancer, such as neurodegenerative diseases. With some proximity-inducing drugs in healthcare development, it is an exciting time for the encouraged proximity research field.

How is AI governing the Induced Proximity Molecules Market?

An AI-based drug discovery platform particularly tailored for designing proximity-inducing small molecules and peptides. An AI-based platform allows the design of bifunctional compounds using a dedicated workflow. The platform uses the paradigm of an iterative design-test-modify advanced loop, where experimental feedback is combined into the design workflow on each iteration. AI-based technology to ensure that the designed chimeras are amphiphilic molecules with a high tendency for membrane crossing. This technology is transforming drug discovery; its tangible impact varies greatly across modalities. Induced-proximity therapeutics have been developed as a powerful modality in drug discovery, allowing the selective removal of disease-causing biomolecules by harnessing endogenous degradation pathways.

Future Outlook & Trends in the Induced Proximity Molecules Market

• Group-transfer chimeras for Inducing Proximity: Group-transfer chimeras for Inducing Proximity (GRIPs), which employ abundantly available effectors' inhibitors to append a POI binder on the effector. Induced-proximity therapeutics have arisen as a significant modality in drug discovery, allowing the selective removal of disease-causing biomolecules by harnessing endogenous degradation pathways.
• Ribonuclease-targeting chimeras: Ribonuclease-targeting chimeras are innovative RNA-targeting molecules that combine small-molecule RNA binders with endogenous RNase L-recruiting moieties.
• Bispecific small-molecule interactome modulators: Bispecific peptides not only hold promise for enhancing therapeutic effectiveness and safety but also offer approaches to overcome the intrinsic restraint of weak binding affinity via cooperative or multivalent target engagement

Quick Facts Table

Segmentation Analysis

By Molecule Type Insights

The PROTACs Segment Led the Induced Proximity Molecules Market in 2025

The PROTACs segment contributed the largest market share of 52% in 2025, as PROTACs afford advanced selectivity compared with traditional inhibitors. PROTACs overcome most of the restraints of the small-molecule inhibitors, and they provide significant advantages over the traditional concepts of drug discovery by besieging protein degradation. PROTACs have the potential to target the undruggable targets that limit conventional drugs, as the warheads need only a slight binding affinity to recruit the POI, rather than high inhibitory activity.

The molecular glues segment held a significant share of 27% in the market and is expected to grow at the fastest CAGR during the forecast period, as molecular glues have evolved as powerful synthetic devices to control biological interactions, manipulate intractable proteins, or target proteins without noticeable binding pockets available to a drug.

The LYTACs segment held a significant share of 13% in the market, as these molecules use the cation-independent mannose-6-phosphate receptor, a well-characterized recycling membrane protein. LYTACs remove circulating pathogenic proteins, involving antibodies or hormones, and modulate cell-surface receptors implicated in metabolic or cardiovascular diseases.

The AUTACs & ATTECs segment held a significant share of 8% in the market, as AUTACs, ATTECs, and related autophagy-based degraders. AUTACs and ATTECs apply small-molecule tags to involve autophagy receptors or LC3, allowing clearance of aggregates, injured organelles, and lipids. ATTEC molecules have significant potential in degrading multiple targets such as pathogenic proteins, lipids, and organelles, and their structural characteristics make them good candidates for drug development.

By Target Protein Class Insights

Kinases Segment Led the Induced Proximity Molecules Market in 2025

The kinases segment contributed the largest market share of 34% in 2025, as a significant advancement in oncology therapy, announcing a novel framework for utilizing kinase-targeting molecules to activate therapeutic gene expression. By converting traditional kinase inhibitors into context-specific activators, CDK-TCIPs provide a versatile and potentially safer approach for targeting transcriptional dysregulation in tumours.

The transcription factors segment held a significant share of 22% of the market, and is expected to grow at the fastest CAGR during the forecast period, as adaptable transcription factors, scaffolding proteins, and signalling adaptors, where partial and context-driven modulation is preferred over complete protein loss. Transcription factors (TFs) are a class of proteins that play a significant role in controlling gene expression by directly binding to specific DNA sequences.

The epigenetic proteins segment held a significant share of 18% of the induced proximity molecules market, as epigenetic mechanisms involve gene regulation by changing chromatin accessibility via changes in transcription factor (TF). Epigenetics regulates gene expression and has been confirmed to play a significant role in a diversity of metabolic diseases.

The GPCRs & membrane proteins segment held a significant share of 18% the market, as G protein-coupled receptors (GPCRs) are extremely sophisticated detection molecules that respond to signals as varied as a photon or a hormone. They are as old as the first multicellular organisms. GPCRs involvrs to many important functions in the human body and play a significant role in health and disease.

By Therapeutic Area Insights

Oncology Segment Led the Induced Proximity Molecules Market in 2025

The oncology segment contributed the largest market share of 58%, as cancer therapeutics, the major application of proximity-inducing molecules, is the targeted degradation of oncogenic proteins. Effective against cancer drivers such as the androgen receptor (AR) and estrogen receptor (ER) in prostate and breast cancers.

The neurological disorders segment held a significant share of 14% in the market, and is expected to grow at the fastest CAGR during the forecast period, as induced-proximity therapeutics evolve as a transformative model in chemical biology and medicinal discovery, allowing selective control of cellular technology. They remove pathogenic proteins that lack active enzymatic sites, like transcription factors and scaffolding proteins.

The immunology & inflammation segment held a significant share of 11% in the market, as proximity-driven agents offer major benefits compared to occupancy-driven agents, like theoretically lower doses, lowering toxicities, and striking selectivity because of enhanced specificity of molecular recognition in the ternary complex formed.

The infectious diseases segment held a significant share of 9% in the market, as induced proximity destroys mutated pathogens that are resistant to conservative inhibitors, which offered the degrader to bind the target. It enables the targeting of proteins that lack outmoded binding pockets, which are typically inaccessible to conventional occupancy-driven drugs.

By End User Insights

Pharmaceutical & Biotechnology Companies Segment Led the Induced Proximity Molecules Market in 2025

The pharmaceutical & biotechnology companies segment contributed the largest market share of 68%, as proximity-based agents are leading to a renaissance of induced molecular recognition for biology and medicine, which could usher in a drug detection paradigm with untapped strength in pharmaceutical and biotechnology organizations.

The academic & research institutes segment held a significant share of 19% in the market, as using chemically induced proximity (CIP) systems in academic & research institutes, researchers initiate or stop protein degradation in minutes. This enables studying the instantaneous consequences of protein depletion, distinguishing direct effects from indirect compensation, and discovering cellular memory.

The contract research organizations (CROs) segment held a significant share of 13% in the market, and is expected to grow at the fastest CAGR during the forecast period, as these molecules reduce the entire protein rather than simply inhibiting its action, they bypass resistance mechanisms such as target overexpression or mutation, providing significant benefits in cancer research programs.

Regional Insight

Why North America Dominated the Market in 2025?

In 2025, North America dominated the induced proximity molecules market with a share of 44% in 2025, as increasing scientific expertise has helped make the U.S. a prosperous nation in the world and led to longer and simpler lives. Major academic institutions are playing an increasingly significant role in drug discovery. Advances in research devices and techniques have greatly improved, which drives the growth of the market.

U.S. Market Trends

In the U.S., advances in research tools and technology have significantly increased the ability to view how DNA, RNA, and proteins shift and interact. Targeted protein degradation (TPD) is a new protein modulation approach distinct from traditional inhibitors.  The U.S. government is the main single funder of biomedical research in the biosphere.

Asia Pacific: A rising Demand for Rapid Diagnostics

Asia Pacific held 20% share of the induced proximity molecules market, and is expected to have the fastest growth during the forecast period, as increasing demand for rapid and precise diagnostic devices has led to amplified partnerships between international organizations and local companies. The largest population is suffering from lifestyle diseases and oncology. This increasing demand for specific oncology treatments drives heavy spending in induced proximity molecules, which contributes to the growth of the market.

India Market Trends

India is evolving from generic synthesis to progressive, targeted protein degradation technology to tackle challenging diseases. Increasing healthcare novelty in India, discovering transformative trends, breakthrough technologies, and approaches shaping the future of the field. The presence of the largest supplier of generic medicines worldwide, supplying one in five generic drugs sold, India has received the title “pharmacy of the world.”

Supply Chain Analysis

R&D:

• R&D processes for induced proximity molecules include target selection and ligand discovery, structural biology and modeling, ternary complex assessment, proteomics and functional screening, and ADME and pharmacokinetic optimization.
• Key Players: Proximity Therapeutics & Triana Biomedicines

Manufacturing Processes:

• The major manufacturing processes for induced proximity molecules such as PROTACs, LYTACs, and molecular glues center on modular assembly, linker chemistry, and high-throughput purification.
• Key Players:  Arvinas and Amgen

Patient Services:

• Patient services are specifically in oncology and neurodegeneration, involving specialized patient services to manage their unique catalytic, event-driven pharmacology.
• Key Players: Plexium Inc.

Latest Updates of Key Players in the Induced Proximity Molecules Market

SWOT Analysis

Strengths

• Induced proximity, which uses small molecules to enable an interaction among two proteins to harness natural biological pathways, shows a revolution in synthetic interaction and drug discovery.
• Induced-proximity therapeutics have evolved as a transformative model in chemical biology and drug discovery, allowing selective control of cellular processes beyond conventional inhibitors.

Weakness

• Major complexities arise during enteral feeding that are typically related to the diameter and rigidity of the tube or the composition, distribution, and sterility of the feed used.

Opportunities

• Targeted protein degradation (TPD) is a promising strategy to eliminate deleterious proteins for therapeutic advantages and to probe biological pathways.
• RIPTACs, a novel class of heterobifunctional molecules, show potential in precisely directing and removing cancer cells while leaving healthy cells unharmed.

Threat

• A bifunctional molecule inadvertently brings an unintended protein into proximity with the effector, producing unwanted stabilization or degradation.

Recent Developments in the Induced Proximity Molecules Market

• In April 2026, an ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG, a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics, announced that Clare Fisher was elected by shareholders
• In November 2025, General Proximity, a biotechnology organization discovering and developing the next generation of induced proximity medicines, announced a strategic multi-target collaboration with Daiichi Sankyo through its Daiichi Sankyo Research Institute in Boston to apply General Proximity's proprietary OmniTAC discovery platform to oncology programs of interest to Daiichi Sankyo.
• In May 2025, VantAI, a frontrunner in generative AI and proximity-based therapeutics, announced that it had entered into a second expansion of its collaboration and license agreement with Blueprint Medicines, a worldwide biopharmaceutical organization, to prioritize targets and design and advance new therapies for areas of high medical need.

Segments Covered in the Report

By Molecule Type

• PROTACs
• Molecular Glues
• LYTACs
• AUTACs & ATTECs

By Target Protein Class

• Kinases
• Transcription Factors
• Epigenetic Proteins
• GPCRs & Membrane Proteins
• Others

By Therapeutic Area

• Oncology
• Neurological Disorders
• Immunology & Inflammation
• Infectious Diseases
• Others

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)

By Stage of Development

• Preclinical
• Phase I
• Phase II
• Phase III & Commercial

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA